Search LIVN
LivaNova PLC
Nasdaq · CIK 1639691
Last close75.07
Daily change+0.37 (0.50%)
10 Years gain+24.21%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
LIVN · STANDARD
SIC 3845 · Electromedical & Electrotherapeutic Apparatus · Fiscal year end 1231
Fundamental
65.1Momentum
61.7Acceleration
61.7Confidence
85.0Annual Revenue12
Quarterly Revenue56
Annual CFO12
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth16.7 / 25
Quality16.8 / 25
Capital Efficiency12.9 / 20
Balance Sheet14.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators4.6 / 5
Signals
Operating leverageOperating margin improved by 2.3457 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM17.19%OK
Revenue CAGR 3Y10.75%OK
Gross Margin68.43%OK
Operating Margin13.61%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC15.56%OK
Incremental Operating Margin 3Y71.79%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.4%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.39B | $939.87M | $199.39M | $254.34M | $173.29M | 67.71% | 14.36% | 12.48% | 12.81% | 54.55M |
| 2025 FY Dec 31, 2024 | $1.25B | $853.48M | $129.05M | $183.04M | $135.93M | 68.09% | 10.3% | 10.84% | 5.93% | 54.57M |
| 2025 FY Dec 31, 2023 | $1.15B | $755.82M | -$68.50M | $74.91M | $39.93M | 65.52% | -5.94% | 3.46% | -3.46% | 54.21M |
| 2024 FY Dec 31, 2022 | $1.02B | $707.23M | -$76.75M | $69.92M | $43.40M | 69.21% | -7.51% | 4.25% | -4.25% | 53.47M |
| 2023 FY Dec 31, 2021 | $1.04B | $705.99M | -$784,000.00 | $102.54M | $77.07M | 68.19% | -0.08% | 7.44% | -0.04% | 50.63M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.46B | sum latest 4 fiscal quarters Revenue | OK | 0001639691-26-000090, 0001639691-25-000150 |
| Revenue Growth TTM | 17.19% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001639691-26-000090, 0001639691-25-000150 |
| Revenue CAGR 3Y | 10.75% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001639691-26-000010 |
| Revenue CAGR 5Y | 8.24% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001639691-26-000010 |
| Gross Profit CAGR 3Y | 9.94% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001639691-26-000010 |
| Operating Income Growth | 41.6% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001639691-26-000090, 0001639691-25-000150 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 68.43% | Gross Profit / Revenue | OK | 0001639691-26-000090, 0001639691-25-000150 |
| Operating Margin | 13.61% | Operating Income / Revenue | OK | 0001639691-26-000090, 0001639691-25-000150 |
| ROIC | 15.56% | NOPAT / Average Invested Capital | OK | 0001639691-26-000090, 0001639691-25-000150 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001639691-26-000090 |
| Current Ratio | 1.45x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.78x | (Cash + Short-term Investments) / Total Debt | OK | 0001639691-26-000090 |
| Revenue per Diluted Share | $26.00 | Revenue / Diluted Shares | OK | 0001639691-26-000090, 0001639691-25-000150 |